<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01244165</url>
  </required_header>
  <id_info>
    <org_study_id>WH-2004-01</org_study_id>
    <nct_id>NCT01244165</nct_id>
  </id_info>
  <brief_title>Study of Cytrix Use in Pelvic Floor Prolapse Treatment</brief_title>
  <official_title>Clinical Investigation of Fetal Bovine Dermis Material (Cytrix) for Use in the Treatment of Pelvic Floor Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate safety and effectiveness of using the fetal bovine dermis (Cytrix) in the
      treatment of pelvic organ prolapse.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients reporting intra-operative complications</measure>
    <time_frame>at procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of treated patients reporting post-operative adverse events</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient healing time</measure>
    <time_frame>6 Months</time_frame>
    <description>length of hospital stay and pain medication</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of complication in Cytrix treated patients compared to patients in the historical control group</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of complication in Cytrix treated patients compared to patients in the historical control group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction after Pelvic Organ Prolapse surgery using Cytrix</measure>
    <time_frame>3 months</time_frame>
    <description>Phone-Patient Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction after Pelvic Organ Prolapse surgery using Cytrix</measure>
    <time_frame>6 months</time_frame>
    <description>Pelvic Floor Distress Inventory (PFDI-SF20) Patient questionnaire, and Pelvic Organ Prolapse Sexual Questionnaire (PISQ-12) Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction after Pelvic Organ Prolapse surgery using Cytrix</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of phone patient questionnaire results between Cytrix Group and Control Group</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of phone patient questionnaire results in Cytrix treated patients compared to patients in the retrospective historical control group where available.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction after Pelvic Organ Prolapse surgery using Cytrix</measure>
    <time_frame>2 wks</time_frame>
    <description>Phone-Patient Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction after Pelvic Organ Prolapse surgery using Cytrix</measure>
    <time_frame>6 wks</time_frame>
    <description>Phone-Patient Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Pelvic Floor Distress Inventory (PFDI-SF20) questionnaire results between Cytrix Group and Control Group</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of Pelvic Floor Distress Inventory (PFDI-SF20) questionnaire results in Cytrix treated patients compared to patients in the retrospective historical control group where available.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician satisfaction in the treatment of patients with pelvic floor prolapse using Cytrix</measure>
    <time_frame>6 months</time_frame>
    <description>Physician satisfaction in the treatment of patients with pelvic floor prolapse using Cytrix versus any other product currently being the standard method of care;
handling characteristics
conformity to the surgical site
ease of suture
procedure length of time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Vaginal Vault Prolapse</condition>
  <arm_group>
    <arm_group_label>Cytrix</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Observational Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with similar indications who were treated at the same centers using other products</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cytrix</intervention_name>
    <arm_group_label>Cytrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Other treatments for pelvic organ prolapse</intervention_name>
    <description>Treatments for pelvic organ prolapse using other products (standard of care for treatment of pelvic organ prolapse)</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female &gt;30 years of age

          -  Willing and able to comply w/ the study procedures and provide written informed
             consent to participate in the study.

          -  Diagnosed with pelvic organ prolapse with or without pelvis floor dysfunction

          -  Patient is willing to complete PFDI-SF20 and PISQ-12 questionnaires at 6 and 12 months
             post-operatively

          -  Patient is willing to answer phone questionnaires at 2 weeks, 6 weeks, and 3 months

          -  Patients with a history of pelvic surgery (cystocele/anterior repair, hysterectomy,
             vault suspension, etc) prior to this procedure are allowed to participate in the study
             except if the patient had a dermal graft implanted.

        Exclusion Criteria:

          -  Patients who, in the clinical judgment of the investigator, are not suitable for this
             study

          -  Patients who are, in the Investigators opinion, mentally or legally incapacitated
             preventing informed consent or unable to read or understand written material.

          -  Patients who have participated in an investigational study within 30 days of study
             entry that may impact analysis of this device or have previously participated in the
             current trial

          -  Patient whose pelvic organ prolapse is Stage I

          -  Patient with Diabetes Mellitus type I or II

          -  Patient with morbid obesity (weight parameters determined by physician)

          -  Patient with undiagnosed pelvic mass outside of the uterus (not expected to be
             functional in nature)

          -  Patient with unexplained abnormal menstrual bleeding

          -  Patient with any acute or chronic infection (kidney, bladder, lung, etc)

          -  Patient with coagulopathy

          -  Patient participating in other investigational device or drug study

          -  Patients must not be pregnant

          -  Patients with life expectancy less than 2 years

          -  Patients with known or suspected hypersensitivity to collagen or bovine products

          -  Patients with preexisting local or systemic infection

          -  Patients with a history of soft tissue pathology where the implant is to be placed

          -  Patients with any pathology that would limit the blood supply and compromise healing

          -  Patient diagnosed with autoimmune connective tissue disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar A Aguirre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milestone Medical Research</affiliation>
  </overall_official>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2010</study_first_posted>
  <last_update_submitted>November 18, 2010</last_update_submitted>
  <last_update_submitted_qc>November 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Janice Connor / Director, Clinical Affairs</name_title>
    <organization>Boston Scientific</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

